Last Price
51.74
Today's Change
-0.56 (1.07%)
Day's Change
51.69 - 52.63
Trading Volume
166,177
Market Cap
3 Billion
Shares Outstanding
68 Million
Avg Volume
517,270
Avg Price (50 Days)
50.88
Avg Price (200 Days)
47.43
PE Ratio
-17.90
EPS
-2.89
Earnings Announcement
31-Oct-2024
Previous Close
52.30
Open
52.33
Day's Range
51.69 - 52.63
Year Range
19.805 - 61.61
Trading Volume
166,177
1 Day Change
-1.07%
5 Day Change
-1.88%
1 Month Change
3.27%
3 Month Change
-8.51%
6 Month Change
26.04%
Ytd Change
80.78%
1 Year Change
132.23%
3 Year Change
76.89%
5 Year Change
213.20%
10 Year Change
415.34%
Max Change
415.34%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.